EVISTA(generic)

On April, 12th the company «Eli Lilly» declared preliminary results of research Raloxifene Use of The Heart Trial (RUTH), large-scale platsebo-supervised research which spent for the purpose of definition, whether reduces reception Evista® (raloxifene a hydrochloride) risk of development of an ischemic heart trouble (IBS) and invasive a cancer of a lung at women in the posmenopausal period with diseases of cardiovascular system or high risk of development IBS. Evista® now it is approved in the USA for the prevention of an osteoporosis and treatment of women during the period postmenopausal period with this disease. Participants of research of a steel of 10 000 patients from 26 countries, the supervision period has made 7 years. The preliminary analysis of results of research on two basic final points testified that reception Evista® does not influence frequency of fatal and not fatal aggravations of diseases of cardiovascular system and the sharp coronary syndrome leading to hospitalisation. Also in comparison with placebo Evista® reduced frequency of occurrence invasive a mammary gland cancer. «As Evista® does not warn development of diseases of cardiovascular system, we wish to focus once again attention of doctors that the preparation should not be appointed for cardioprotection», — Alan Brejer, the vice-president and the head of medical department of the company «Eli Lilly» has told. «Doctors should be informed that by results of RUTH moderate decrease in level lyporpotheids the low density, revealed at earlier researches of a preparation and reflected in the instruction to Evista®, does not render influence on cardioprotection», — the representative «Eli Lilly» has noted.

Tags: Evista, heart troubles, Raloxifene

This entry was posted on Пятница, Октябрь 2nd, 2009 at 0:51 and is filed under Pharmacy news, Woman Health. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.